LMWH
[용어속성] Drug
Peripheral blood microRNAs and the COVID-19 patient: methodological considerations, technical challenges and practice points
말초혈액 microRNA와 COVID-19 환자: 방법론적 고려사항, 기술적 과제 및 실천 포인트
Review
[키워드] acute respiratory distress
acute respiratory distress syndrome
acute respiratory syndrome
acute respiratory syndrome coronavirus
acute respiratory syndrome coronavirus-2
addressed
among others
Analysis
angiotensin
Angiotensin-converting enzyme
ARDS
Biomarker
biopsies
Blood
circulating
circulating miRNA profile
circulating miRNA profiles
Clinical practice
coronavirus
coronavirus disease
Coronavirus disease 2019
COVID-19
COVID-19 emergency
COVID-19 patients
detection
Early detection
experimental design
heparin
infection with SARS-CoV-2
Interpretation
liquid biopsy
LMWH
low molecular weight
low molecular weight heparin
management
methodological
Methods
microRNA
MicroRNAs
miRNA
miRNA signature
miRNAs
ncRNA
noncoding RNA
pandemic
peripheral
public health
qPCR
reproducibility
respiratory
respiratory distress
resulting
rigour
robust
RT-qPCR
SARS-CoV-2
Severe acute respiratory syndrome
severe acute respiratory syndrome Coronavirus
transcriptomic
translation
variable
[DOI] 10.1080/15476286.2021.1885188 PMC 바로가기 [Article Type] Review
[DOI] 10.1080/15476286.2021.1885188 PMC 바로가기 [Article Type] Review
Suggestions for global coagulation assays for the assessment of COVID-19 associated hypercoagulability
COVID-19 관련 과응고성 평가를 위한 글로벌 응고 분석에 대한 제안
Article
[키워드] acute respiratory syndrome
acute respiratory syndrome coronavirus
addition
adjusted
Alter
Analysis
Anticoagulant
change
Clotting time
coagulant
Coagulation
Coagulopathy
condition
conditions
coronavirus
COVID-19
decrease
Diagnosis
diagnostic
dose
effective
Effectiveness
ellagic acid
expected
fibrinogen
Fibrinogen levels
fibrinolytic
Final
Follow-up
healthy volunteers
heparin
heparins
HPPH
hypercoagulability
ICU Patients
Infection
influence
influences
inhibitory effect
LMWH
material
normalized
outcome
parameters
pathophysiological mechanism
patients
phenotype
plasma
Population
Prognosis
prothrombotic
protocol
quantification
reagent
risk
ROTEM
SARS-CoV2
sensitivity
severe acute respiratory syndrome Coronavirus
severe acute respiratory syndrome coronavirus 2
suggestion
thrombin
Thrombin generation
thrombosis
tissue
Tissue Factor
triggered
Variability
variants
was performed
was used
[DOI] 10.1016/j.thromres.2021.02.026 PMC 바로가기 [Article Type] Article
[DOI] 10.1016/j.thromres.2021.02.026 PMC 바로가기 [Article Type] Article
Cellular Immune Response to COVID-19 and Potential Immune Modulators
COVID-19 및 잠재적 면역 조절제에 대한 세포 면역 반응
Review
[키워드] acute respiratory syndrome
addition
Administered
Anergy
Antibiotics
anticoagulation
caused
Cellular immune response
characteristic
characterized
Clinical outcome
Contact
coronavirus
Coronavirus disease 2019
COVID-19
Critical
died
Diseases
droplet
Factor
Factors
glucocorticoid
heterogeneous
Host
Hyperactivation
IFN
immune
immune response
include
Intravenous immunoglobulin
LMWH
low molecular weight
Mild
modulator
no symptom
outcome
Patient
patients
Potential
potential immune modulators
previous study
respiratory infectious disease
response
SARS-CoV-2
severe COVID-19
severity of COVID-19
the disease
the patient
therapy
transmission of SARS-CoV-2
type I interferon
viral infection
virus
[DOI] 10.3389/fimmu.2021.646333 PMC 바로가기 [Article Type] Review
[DOI] 10.3389/fimmu.2021.646333 PMC 바로가기 [Article Type] Review
Thrombose und COVID-19
SARS-CoV-2
Published on
Journal: Hautnah Dermatologie Und Allergologie Fu¨r A¨rzte Und Apotheker [Category] COVID-19,
Journal: Hautnah Dermatologie Und Allergologie Fu¨r A¨rzte Und Apotheker [Category] COVID-19,
[키워드] acute respiratory syndrome
Coagulopathy
Coronavirus-2
COVID-19
Inflammation
Koagulopathie
LMWH
manifestation
pandemic
Pandemie
RCTs
SARS-CoV‑2
SARS-CoV‑2
Venöse Thromboembolie
Venen
Venous Thromboembolism
VTE
[DOI] 10.1007/s12326-021-00438-6 PMC 바로가기 [Article Type] SARS-CoV-2
[DOI] 10.1007/s12326-021-00438-6 PMC 바로가기 [Article Type] SARS-CoV-2
Digital Ischemia as an Initial Presentation in a COVID-19-Positive Patient Without Any Significant Respiratory Symptoms
Cardiology
[키워드] ARDS
Coagulopathy
Coronavirus disease 2019
COVID-19
critically ill patients
Digital
digital ischemia
distress
Ischemia
limb
LMWH
multiorgan failure
Patient
presentation
reported
respiratory
Significant
significant respiratory symptoms
syndrome
thrombosis
thumb
[DOI] 10.7759/cureus.14054 PMC 바로가기 [Article Type] Cardiology
[DOI] 10.7759/cureus.14054 PMC 바로가기 [Article Type] Cardiology
Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG – RAPID Trial): A structured summary of a study protocol for a randomised controlled trial
입원한 COVID-19의 응고병증: COVID-19 유행병에 대한 신속한 대응으로서 치료용 항응고제 대 표준 치료의 실용적인 무작위 통제 시험(RAPID COVID COAG – RAPID 실험): 무작위 통제 실험을 위한 연구 프로토콜의 구조화된 요약
Letter
[키워드] 1:1
absence
acutely ill hospitalized medical patients
Admission
age
allergy
allocation concealment
allocation sequence
Alpha
America
and protocol
Anticoagulant
anticoagulation
antiplatelet
antithrombotic therapy
apixaban
arterial
bleeding
bleeding risk
Blinding
block sizes
blood cell
Brazil
can not
Canada
Care
Chain Reaction
changed
choice
clinical trial
clinically
clinician
Coagulation
Coagulopathy
Committee
complex
Composite
computer-generated
contraindication
control group
Controlled
COVID
COVID-19
Critical
Critical illness
cryoprecipitate
D-dimer
D-dimer value
Dabigatran
dalteparin
Date
death
defined
dependent on
detect
determine
diagnosis of SARS-CoV-2
diagnostic
Diagnostic imaging
discretion
disorder
dissemination
dose
dual
edoxaban
electrocardiogram
element
elevated
emergency room
enoxaparin
Enrollment
evaluated
exclusion criteria
expected
experimental group
fibrinogen
fondaparinux
frozen plasma
Health Organization
hemoglobin
heparin
heparin-induced thrombocytopenia
High dose
high risk
hospital
Hospital admission
hospitalised
Hospitalized
hospitalized patient
hospitalized patients
ICU
ICU admission
include
inclusion criteria
indicated
individual
inflammatory biomarkers
Informed consent
INR
intensive care
intensive care unit
Interactive Web Response System
intermediate dose
Invasive mechanical ventilation
involved
Ireland
isothermal amplification
judgement
limit
LMWH
Local
low molecular weight
low molecular weight heparin
Major
major bleeding
mechanical ventilation
Non-invasive
non-invasive positive pressure ventilation
nucleic acid
number
objective
occur
Open-label
open-label trial
outcome
oxygen
oxygen saturation
participant
Patient
patients
Phase 3
plasma
Platelet
Platelet count
Platelets
polymerase chain
polymerase chain reaction
positive pressure
positive pressure ventilation
power
Pregnancy
pressure ventilation
protocol
random
random allocation
randomised
randomised controlled trial
randomization
Randomized controlled trial
Rapid
recruited
red blood cell
renal replacement therapy
replacement therapy
response
responsible
reverse transcriptase
Reverse transcriptase polymerase chain reaction
risk
risk difference
rivaroxaban
room air
Sample size
Saudi Arabia
secondary
Secondary outcomes
Standard
standard care
status
stratified
study population
Study protocol
supplementary material
symptomatic
the patient
the United State
therapeutic anticoagulation
therapeutic dose
therapy
thrombocytopenia
Thromboembolism
Thromboprophylaxis
tinzaparin
transcriptase
transfusion
treated
Trial
Trial registration
two-sided
ULN
unfractionated heparin
United Arab Emirates
United States
Venous Thromboembolism
Ventilator-free days
Version
Warfarin
website
World Health Organization
[DOI] 10.1186/s13063-021-05076-0 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-021-05076-0 PMC 바로가기 [Article Type] Letter
Clinical Management of Hypertension, Inflammation and Thrombosis in Hospitalized COVID-19 Patients: Impact on Survival and Concerns
Article
[키워드] ACE2
acute respiratory syndrome
Analysis
angiotensin receptor blocker
angiotensin-converting enzyme 2
Anticoagulant
antihypertensive agents
Arterial hypertension
Asturia
caused
clinical
Clinical management
clinical manifestation
Cohort
Comorbidities
Comorbidity
concern
contrary
coronavirus
Coronavirus disease 2019
Corticosteroid
Corticosteroids
covariates
COVID-19
COVID-19 patient
COVID-19 patients
Cox regression
Demographic variables
detrimental
diabete
Effectiveness
hospitalized patient
hospitalized patients
immune response
Impact
IMPROVE
Inflammation
inhibitor
LMWH
low molecular weight
management
non-steroidal anti-inflammatory drug
NSAIDS
patients
pro-thrombotic
propensity score matching
reported
Retrospective study
Risk factors
SARS-CoV-2
significantly
Spanish
specific treatment
survival
Survival curves
thrombosis
Thrombosis prophylaxis
Treatment
treatment arm
while
[DOI] 10.3390/jcm10051073 PMC 바로가기 [Article Type] Article
[DOI] 10.3390/jcm10051073 PMC 바로가기 [Article Type] Article
Clinical outcome with different doses of low-molecular-weight heparin in patients hospitalized for COVID-19
Article
[키워드] 95% CI
acute respiratory distress
adverse event
all-cause mortality
Anticoagulant
appear
ARDS
association
clinical
consecutive patient
COVID-19
death
different dose
dosage
dose
doses
Enoxaparin doses
evaluated
higher risk
hospitals
In-hospital
In-hospital death
incidence
intubation
Italian
LMWH
low molecular weight
mechanical ventilation
Mortality
multivariable analysis
outcome
outcome measure
overall mortality
Patient
patients hospitalized
patients with COVID-19
primary end-point
pro-thrombotic
Prophylactic
prophylactic dose
Randomized
regimen
secondary
significantly lower
suggested
supplementary material
syndrome
Thromboprophylaxis
thrombotic event
treated
Treatment
Venous Thromboembolism
[DOI] 10.1007/s11239-021-02401-x PMC 바로가기 [Article Type] Article
[DOI] 10.1007/s11239-021-02401-x PMC 바로가기 [Article Type] Article
Impact of low molecular weight heparin administration on the clinical course of the COVID-19 disease
Article
[키워드] 95% CI
administration
Analysis
analyzed
antiinflammatory
biochemical
C-reactive protein (CRP
characteristic
Clinical course
clinical impact
Clinical symptoms
control group
coronavirus disease
Coronavirus disease-19
COVID-19
COVID-19 disease
criterion
CRP
CRP level
D-dimer
demonstrated
diagnosed with COVID-19
hematologic
heparin
Impact
improvement
Laboratory
LMWH
low molecular weight
lymphocyte
Lymphocyte count
Lymphocytes
material
medical records
Mortality
multivariable analysis
outcomes
participant
Patient
radiologic
Result
ROC
separated
significantly
the patient
treated
Treatment
treatment group
[DOI] 10.3906/sag-2006-184 PMC 바로가기 [Article Type] Article
[DOI] 10.3906/sag-2006-184 PMC 바로가기 [Article Type] Article